Format

Send to

Choose Destination
Int J Lab Hematol. 2017 Dec;39(6):577-584. doi: 10.1111/ijlh.12700. Epub 2017 Jun 18.

A single-tube flow cytometric procedure for enhancing the diagnosis and prognostic classification of patients with myelodysplastic syndromes.

Author information

1
Department of Laboratory Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
2
Department of Pathology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
3
Department of Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
4
Department of Hematology, Jósa András County Hospital, Nyíregyháza, Hungary.

Abstract

INTRODUCTION:

We created a simple and effective flow cytometry scoring system (FCSS) for suspected Myelodysplastic syndromes (MDS) samples and evaluated its diagnostic and prognostic potential.

METHODS:

Besides evaluating the four parameters suggested by Ogata, we investigated erythroid precursors and mast cells. We evaluated the six-parameter FCSS in a four-color setting (test cohort: 51 patients; 25 controls), then we implemented it into an eight-color setting and tested it on a validation cohort of patients with MDS (n=31).

RESULTS:

When we compared MDS cases to non-MDS samples in the test cohort, we detected significant differences regarding not only the four major parameters but also two additional ones, namely CD71 rCV% of erythroid precursors (P=.004) and mast cell percentage (MC%) (P=.001). The utilization of the modified six-parameter FCSS provided high sensitivity and specificity both in the four color (84% and 80%, respectively) and in the eight color (81% and 100%, respectively) setting, with an excellent discriminative power between MDS and non-MDS samples. Furthermore, we found significant difference in event-free survival between the risk groups based on the modified six-parameter FCSS (P=.001).

CONCLUSION:

We evaluated and validated a single-tube flow cytometric procedure for a simple six-parameter FCSS which has not only high diagnostic but also prognostic power.

KEYWORDS:

Myelodysplastic syndrome; erythroid CD71; flow cytometry scoring system; mast cell; rare events

PMID:
28625017
DOI:
10.1111/ijlh.12700
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center